The use of same in chemotherapy-induced liver injury

Antonio Russo, Antonio Galvano, Russo, Antonio Galvano, Vorini, Umberto Vespasiani-Gentilucci, Raffaele Antonelli-Incalzi, Daniele Santini

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)


Drug-induced liver injury (DILI) remains the most common cause of acute liver failure in the Western world. Chemotherapy is one of the major class of drugs most frequently associated with idiosyncratic DILI. For this reason, patients who receive chemotherapy require careful assessment of liver function prior to treatment to determine which drugs may not be appropriate and which drug doses should be modified. S-adenosylmethionine (SAMe) is an endogenous agent derived from methionine. Its supplementation is effective in the treatment of liver disease, in particular intrahepatic cholestasis (IHC). The target of this review is to analyze the mechanisms of hepatotoxicity of the principal anticancer agents and the role of SAMe in the prevention of this complication.
Original languageEnglish
Pages (from-to)70-77
Number of pages8
Publication statusPublished - 2018

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology


Dive into the research topics of 'The use of same in chemotherapy-induced liver injury'. Together they form a unique fingerprint.

Cite this